WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 44'6601 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 47'8041 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 4'677  4'627  4'576  4'523  4'468  3'804  3'531  3'418 
Births 71  71  71  71  71  57  51  69 
Surviving infants 71  71  71  71  71  57  51  68 
Pop. less than 5 years 361  363  364  360  351  268  280  349 
Pop. less than 15 years 1'011  1'000  988  973  954  828  954  1'038 
Female 15-49 years 1'161  1'159  1'157  1'155  1'152  994  865  769 

Number of reported case

(Click for retrospective incidence data for Ireland)
Diphtheria
Japanese encephalitis
Measles 33  51  107  285  443  556  1'106 
Mumps 762  228  170  177  308 
Pertussis 73  175  458  229  107  803  547 
Polio*
Rubella 10  29 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)**
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Ireland)
Vaccine year result method % card seen                                                
BCG          86  86  80  85  96 
DTP1         
DTP3          96  96  95  95  94  86  65  34 
DTP4         
IPV1         
HepB_BD         
HepB3          95  95  95  95  94 
Hib3          96  95  95  95  94  85 
JapEnc         
MCV1          93  92  92  92  90  79 
MCV2         
PCV1         
PCV3          92  91  91  90  88 
Pol3          96  96  95  95  94  86  81  72 
Rota1         
Rota_last         
Rubella1          93  92  92  92  90 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Ireland)
BCG 74  76  42  41  30  89  84 
DTP1 98  98  98  98  98  95  85  59 
DTP3 96  96  95  95  94  86  65  34 
HepB3 95  95  95  95  46 
HepB_BD
Hib3 96  95  95  95  94  85 
MCV1 93  92  92  92  90  79  78 
MCV2
PCV3 92  91  91  90  43 
Pol3 96  96  95  95  94  86  81  72 
Rota_last

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; No
DTaPHibHepIPV 2, 4, 6 months; Yes
DTaPIPV 4-5 years; Yes
HIB 13 months; Yes
HPV 12-13 years; +5 months;
HepB +0, +1, +5 months; Yes Persons with occupational risk of exposure to blood or blood contaminated environments, Family and household contacts, Injecting drug users and their contacts, Individuals at high risk due to medical conditions, Members of other high risk groups
Influenza_Adult elderly, pregnant women, health care workers, adults with chronic diseases and other risk groups
Influenza_Pediatric children with chronic diseases
MMR 12 months; 4-5 years; Yes Also given to HCW and during outbreaks and other risk groups
MenC_conj 4, 6, 13 months; Yes
Pneumo_conj 2, 6, 12 months; Yes
Pneumo_ps >=65 years; Yes And children >=2 years at risk;
Tdap 11-14 years; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  Yes    Yes  Yes  NA  Yes 
What years does the MYP cover? number   2013-2014    2011 -2012  2010 -2011    2008-2010 
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number
Nº districts with DTP3 coverage >=80% number
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number
% of districts with MCV1 coverage >=95% From 0 to 100% 25  38  25  13 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND   Yes    Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR   Yes    Yes  Yes    Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%   90    90  90    90 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.